Eglumegad
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Eglumegad.png | |
| Eglumegad
| |
| Systematic (IUPAC) name | |
| (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C8H11NO4 |
| Mol. mass | 185.18 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Eglumegad (LY-354,740) is a research drug developed by Eli Lilly, which is being investigated for its potential in the treatment of anxiety[1] and drug addiction.[1] It is a glutamate derived compound and its mode of action implies a novel mechanism.[1]
Eglumegad acts as a group-selective agonist for the group II metabotropic glutamate receptors (mGluR2/3).[1][1] A substantial D2 dopaminergic component was also found.[1]
In experiments on mice, eglumegad was found to be as effective as diazepam for treating anxiety symptoms in several standard tests, but without producing any of the negative side effects of diazepam such as sedation and memory impairment.[1] Tests in humans confirmed that it produced anxiolytic effects without producing sedation.[1][1] However it did slightly reduce cognitive performance in tests on monkeys.[1]
Eglumegad has also been found to be effective in relieving the symptoms of withdrawal from chronic use of both nicotine[1] and morphine in animals,[1] as well as inhibiting the development of tolerance to morphine,[1] raising hope that this drug may be useful for treating drug addiction in humans.
Eglumegad and related drugs are neuroprotective[1] and are synergistic with the neuroprotection produced by NMDA antagonist drugs,[1] which may make these drugs useful in aiding recovery from brain injury.
This class of drugs also interacts with hallucinogenic drugs, with eglumegad reducing the effects of 5HT2A agonist hallucinogens,[1] while conversely the mGluR2/3 antagonist LY-341,495 increased the behavioural effects of these drugs.[1] This suggests that mGluR2/3 agonists such as eglumegad may have potential uses in the treatment of some forms of psychosis, although eglumegad had only limited effects on the action of the dissociative drug phencyclidine[1] which is generally a better model for schizophrenia than the 5HT2A agonist hallucinogens.[1]
Development of this drug is continuing, with several clinical trials completed and more planned.[1] Poor oral bioavailability of the original formulation led to limited efficacy in the initial human trials,[1] and so the prodrug form LY-544,344 looks more likely to be the final canditate for aspired marketing.[1][1][1]
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
